↓ Skip to main content

Mitochondria-Targeted Drugs Synergize with 2-Deoxyglucose to Trigger Breast Cancer Cell Death

Overview of attention for article published in Cancer Research, May 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (83rd percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

twitter
2 X users
patent
14 patents
facebook
1 Facebook page
wikipedia
1 Wikipedia page

Citations

dimensions_citation
201 Dimensions

Readers on

mendeley
168 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Mitochondria-Targeted Drugs Synergize with 2-Deoxyglucose to Trigger Breast Cancer Cell Death
Published in
Cancer Research, May 2012
DOI 10.1158/0008-5472.can-11-3928
Pubmed ID
Authors

Gang Cheng, Jacek Zielonka, Brian P. Dranka, Donna McAllister, A. Craig Mackinnon, Joy Joseph, Balaraman Kalyanaraman

Abstract

Cancer cells are long known to exhibit increased aerobic glycolysis, but glycolytic inhibition has not offered a viable chemotherapeutic strategy in part because of the systemic toxicity of antiglycolytic agents. However, recent studies suggest that a combined inhibition of glycolysis and mitochondrial function may help overcome this issue. In this study, we investigated the chemotherapeutic efficacies of mitochondria-targeted drugs (MTD) in combination with 2-deoxy-d-glucose (2-DG), a compound that inhibits glycolysis. Using the MTDs, termed Mito-CP and Mito-Q, we evaluated relative cytotoxic effects and mitochondrial bioenergetic changes in vitro. Interestingly, both Mito-CP and Mito-Q synergized with 2-DG to decrease ATP levels in two cell lines. However, with time, the cellular bioenergetic function and clonogenic survival were largely restored in some cells. In a xenograft model of human breast cancer, combined treatment of Mito-CP and 2-DG led to significant tumor regression in the absence of significant morphologic changes in kidney, liver, or heart. Collectively, our findings suggest that dual targeting of mitochondrial bioenergetic metabolism with MTDs and glycolytic inhibitors such as 2-DG may offer a promising chemotherapeutic strategy.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 168 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 1%
United Kingdom 2 1%
Japan 2 1%
Chile 1 <1%
Russia 1 <1%
Unknown 160 95%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 44 26%
Researcher 42 25%
Student > Master 13 8%
Student > Bachelor 10 6%
Professor > Associate Professor 8 5%
Other 24 14%
Unknown 27 16%
Readers by discipline Count As %
Agricultural and Biological Sciences 47 28%
Biochemistry, Genetics and Molecular Biology 34 20%
Medicine and Dentistry 19 11%
Chemistry 12 7%
Pharmacology, Toxicology and Pharmaceutical Science 9 5%
Other 17 10%
Unknown 30 18%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 January 2024.
All research outputs
#4,432,723
of 24,836,260 outputs
Outputs from Cancer Research
#4,186
of 18,980 outputs
Outputs of similar age
#28,505
of 168,403 outputs
Outputs of similar age from Cancer Research
#41
of 269 outputs
Altmetric has tracked 24,836,260 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 18,980 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.3. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 168,403 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 269 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.